Technical Analysis for CYCCP - Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Grade Last Price % Change Price Change
F 6.94 0.00% 0.00
CYCCP closed unchanged on Wednesday, November 20, 2024, on 7 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Bullish Engulfing Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Outside Day Range Expansion 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Narrow Range Bar Range Contraction 4.99%
Gapped Down Weakness 4.99%
Oversold Stochastic Weakness 4.99%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High 2 days ago
Rose Above 10 DMA 2 days ago
Outside Day 2 days ago
Down 5% 2 days ago
Down 3% 2 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock Description

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Treatment Of Cancer Cell Biology Inflammatory Diseases Cancer Cell Autoimmune And Inflammatory Disease Human Cancers Cell Cycle Cyclacel Cyclin Dependent Kinase Dna Synthesis PLK1 Cdk Inhibitor Cell Cycle Checkpoint Cyclin Dependent Kinase 2 Sapacitabine Seliciclib

Is CYCCP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 22.2
52 Week Low 5.2096
Average Volume 1,467
200-Day Moving Average 12.41
50-Day Moving Average 8.19
20-Day Moving Average 6.99
10-Day Moving Average 6.81
Average True Range 0.54
RSI (14) 46.24
ADX 19.65
+DI 26.74
-DI 48.76
Chandelier Exit (Long, 3 ATRs) 6.39
Chandelier Exit (Short, 3 ATRs) 7.19
Upper Bollinger Bands 7.73
Lower Bollinger Band 6.25
Percent B (%b) 0.47
BandWidth 21.26
MACD Line -0.34
MACD Signal Line -0.39
MACD Histogram 0.0546
Fundamentals Value
Market Cap 86.73 Million
Num Shares 12.5 Million
EPS -2.05
Price-to-Earnings (P/E) Ratio -3.39
Price-to-Sales 99.96
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.94
Resistance 3 (R3) 6.94 6.94 6.94
Resistance 2 (R2) 6.94 6.94 6.94 6.94
Resistance 1 (R1) 6.94 6.94 6.94 6.94 6.94
Pivot Point 6.94 6.94 6.94 6.94 6.94
Support 1 (S1) 6.94 6.94 6.94 6.94 6.94
Support 2 (S2) 6.94 6.94 6.94 6.94
Support 3 (S3) 6.94 6.94 6.94
Support 4 (S4) 6.94